By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Tethys Bioscience today said that it has raised $33 million in venture financing and a loan.

The Emeryville, Calif.-based firm, which is developing biomarker-based, disease-risk tests, has raised $23 million in venture financing through new investors, including Greenspring Associates and Paul Capital Investments, and its current investors. The funds are part of Tethys' Series D round, bringing the total funding in that round to $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.